A Phase IIIb Study to Evaluate the Safety and Efficacy of Gemigliptin in Type 2 Diabetes Mellitus Patients With Moderate or Severe Renal Impairment(GUARD Study)

NCT01968044 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

132

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 2 DM Patients With Moderate or Severe Renal Impairment

Interventions

DRUG: Gemigliptin
DRUG: Placebo to Linagliptin

Sponsor

LG Life Sciences